40
Participants
Start Date
June 30, 2016
Primary Completion Date
April 30, 2020
Study Completion Date
April 30, 2020
Tesevatinib
Columbia University, Herbert Irving Comprehensive Cancer Center, New York
Cleveland Clinic, Cleveland
Henry Ford Hospital, Detroit
UT MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
Huntsman Cancer Institute, Salt Lake City
Center for Neurosciences, Tucson
City of Hope, Duarte
University of California, San Francisco (UCSF), San Francisco
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Kadmon Corporation, LLC
INDUSTRY